Hims & Hers Health (NYSE:HIMS) Upgraded at Needham & Company LLC

Hims & Hers Health (NYSE:HIMS) was upgraded by investment analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The firm currently has a $30.00 target price on the stock. Needham & Company LLC’s price objective points to a potential upside of 35.44% from the stock’s previous close.

HIMS has been the topic of a number of other research reports. Barclays lowered their price objective on Hims & Hers Health from $48.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Hims & Hers Health and gave the company a “hold” rating in a research report on Tuesday, February 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. BTIG Research downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Finally, Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Three investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $29.77.

Hims & Hers Health Trading Up 40.7%

NYSE:HIMS traded up $6.41 on Monday, hitting $22.15. The stock had a trading volume of 104,888,658 shares, compared to its average volume of 29,553,262. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The stock has a market cap of $5.05 billion, a price-to-earnings ratio of 43.43, a PEG ratio of 3.01 and a beta of 2.55. The company has a fifty day moving average price of $24.75 and a two-hundred day moving average price of $38.05. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same period in the previous year, the company posted $0.11 EPS. Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has initiated a stock buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael Chi sold 13,750 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 82,963 shares of company stock valued at $2,944,621 over the last 90 days. Corporate insiders own 13.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the stock. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the 2nd quarter worth about $26,000. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $28,000. Binnacle Investments Inc purchased a new position in Hims & Hers Health in the third quarter worth approximately $28,000. Finally, Bogart Wealth LLC grew its position in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the period. 63.52% of the stock is owned by institutional investors.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk agreed to sell Wegovy and Ozempic via Hims & Hers and dropped its lawsuit, formally ending the public dispute and clearing a legal overhang that had pressured the stock. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Hims & Hers and Novo announced a collaboration to bring FDA‑approved GLP‑1 treatments (injectable and oral semaglutide options) to HIMS’ U.S. platform, representing a strategic pivot into high‑growth obesity care. Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute
• Positive Sentiment: Market reaction: multiple outlets report an outsized rally (pre‑market and early trading), reflecting investor relief and bullish positioning on HIMS’ access to GLP‑1 demand. Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs
• Neutral Sentiment: Context and quick takes: several financial outlets summarize the deal and market implications; analysts will need time to model revenue/earnings impact because commercial terms were not disclosed. Hims and Hers Stock Pops on a Deal With Rival Novo Nordisk—What You Need to Know
• Neutral Sentiment: Market commentary: traders noted this could be HIMS’ biggest one‑day gain ever as the company shifts from selling compounded alternatives to distributing branded GLP‑1s via its platform. HIMS Stock Eyes Best Day Ever After Dispute Dissolution
• Negative Sentiment: Risks and limits: Novo retained the right to revive litigation if terms are breached, and HIMS agreed to stop promoting compounded GLP‑1 products and to sell Novo’s drugs at parity with other telehealth platforms — moves that could cap margin upside and leave commercial economics unclear. Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.